Filipiak Louis, Paydary Koosha, Fidler Mary Jo, Ross Helen J
Department of Medicine, Section of Hematology, Medical Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL 60612, USA.
Cancers (Basel). 2025 Jul 25;17(15):2462. doi: 10.3390/cancers17152462.
Immune checkpoint inhibitors (ICIs) are approved in at least one line of therapy for most patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK alterations and have improved survival for a subset of patients. Adjuvant, neoadjuvant, and perioperative therapy for resectable NSCLC carries the hope of more broadly increased cure rates for patients with resectable lung cancers. This review summarizes the current state of multimodality management, including ICIs, for resectable NSCLC. A literature search of PubMed and Scopus identified phase II and III clinical trials including ICIs in patients with resectable NSCLC. No level 1 evidence guides the clinician in choosing between the available neoadjuvant and perioperative approaches.
免疫检查点抑制剂（ICIs）已被批准用于大多数无EGFR/ALK改变的晚期非小细胞肺癌（NSCLC）患者的至少一线治疗，并提高了一部分患者的生存率。可切除NSCLC的辅助、新辅助和围手术期治疗为可切除肺癌患者带来了更广泛提高治愈率的希望。本综述总结了可切除NSCLC的多模式管理现状，包括ICIs。对PubMed和Scopus进行文献检索，确定了包括可切除NSCLC患者使用ICIs的II期和III期临床试验。没有一级证据指导临床医生在现有的新辅助和围手术期方法之间做出选择。
